TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
PYC Therapeutics Limited ( (AU:PYC) ) just unveiled an update.
PYC Therapeutics Limited has announced changes in its board of directors, with new appointments and final interest notices for several directors. These changes are part of the company’s ongoing efforts to strengthen its leadership team as it continues to advance its RNA therapeutic programs, which could impact its market positioning and stakeholder interests.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.85 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company focused on developing RNA therapies for genetic diseases. The company uses a proprietary drug delivery platform to enhance the effectiveness of precision medicines, targeting monogenic diseases with high clinical development success rates.
Average Trading Volume: 886,850
Technical Sentiment Signal: Sell
Current Market Cap: A$522M
Learn more about PYC stock on TipRanks’ Stock Analysis page.